| (1) | A company on a mission to improve the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells. |
| (2) | A lead product in clinical development which has successfully completed Phase I/IIa trials and completed treatment in Phase IIb clinical trials with a view to obtaining provisional consent to treat paying patients with Parkinson's disease in 2018. |
| (3) | NTCELL addresses a high unmet medical need in an expanding market. |
| (4) | Animal studies show that NTCELL has the potential to be useful in a range of diseases. |
| (5) | Sound finances & safe hands |
updated 16th August, 2017
| © Copyright 1996-2019 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |